Articles related to ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)

Among 90 pediatric patients with relapsed or refractory B-cell precursor ALL, prior blinatumomab was associated with more relapses at atypical extramedullary sites. The retrospective single-center findings require prospective confirmation.

A retrospective cohort of 146 adult patients with T-cell ALL treated with a pediatric-inspired regimen at a single center achieved 3-year overall survival of 73% and leukemia-free survival of 77%, with age over 60 emerging as the primary adverse prognostic factor and early T-cell precursor phenotype showing no independent survival impact.

Silent inactivation (where neutralizing antibodies reduce enzymatic activity without clinical symptoms) can go undetected without therapeutic drug monitoring, leading to subtherapeutic asparagine depletion and increased relapse risk.

Chemotherapy-free regimens for Ph+ ALL have shown complete response rates of 94-100% with minimal toxicity, potentially eliminating the need for stem cell transplant in many patients.

The combination of ponatinib and blinatumomab demonstrated a 95% complete response rate and 91% 3-year overall survival rate in patients with Ph-positive ALL.

Menin inhibitors, targeting the menin-KMT2A interaction, have demonstrated significant response rates in treating specific genotypes of AML and ALL, offering a new avenue for personalized leukemia therapy.